Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study
Open Access
- 30 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 213
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Company
This publication has 29 references indexed in Scilit:
- International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trialsQuality of Life Research, 2023
- Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic CancerJAMA, 2022
- Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug ClassJAMA Oncology, 2022
- The use of patient-reported outcomes (PROs) in cancer care: a realistic strategyAnnals of Oncology, 2022
- General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites StatesEuropean Journal of Cancer, 2019
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in OncologyJAMA Internal Medicine, 2018
- Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trialsCancer, 2018
- The longitudinal relationship between quality of life and survival in advanced stage cancerPsycho-Oncology, 2015
- A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sitesCancer, 2013
- Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanomaEuropean Journal of Cancer, 1993